Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands

Transfusion

Volumn 46, Issue 6, 2006, Pages 956-965

  Janssen, Mart P ^a   Van Der Poel, Cees L ^a   Buskens, Erik ^a   Bonneux, Luc ^a   Bonsel, Gouke J ^a   Van Hout, Ben A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE CONCENTRATE;

ARTICLE; BACTERIAL COUNT; BACTERIUM CONTAMINATION; BACTERIUM CULTURE; BACTERIUM ISOLATION; BLOOD BANK; BLOOD SAMPLING; CONFIDENCE INTERVAL; COST BENEFIT ANALYSIS; INTERMETHOD COMPARISON; MATHEMATICAL MODEL; MATHEMATICAL PARAMETERS; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MONTE CARLO METHOD; NETHERLANDS; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RECIPIENT; RISK REDUCTION; SEPARATION TECHNIQUE; SEPSIS; SURVIVAL; THROMBOCYTE TRANSFUSION; UNCERTAINTY;

BACTERIOLOGICAL TECHNIQUES; BLOOD-BORNE PATHOGENS; COST-BENEFIT ANALYSIS; HUMANS; NETHERLANDS; PLATELET TRANSFUSION; SEPSIS; SURVIVAL RATE;

EID: 33744486877     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.00828.x     Document Type: Article

References (50)

1. Goodnough LT, Brecher ME, Kanter MH, et al. Transfusion medicine. First of two parts - blood transfusion. N Engl J Med 1999 340 : 438 47.
2. Hillyer CD, Josephson CD, Blajchman MA, et al. Bacterial contamination of blood components: risks, strategies, and regulation: Joint ASH and AABB Educational Session in Transfusion Medicine. Hematology (Am Soc Hematol Educ Program) 2003 : 575 89.
3. Goodman C, Chan S, Collins P, et al. Ensuring blood safety and availability in the US: technological advances, costs, and challenges to payment - final report. Transfusion 2003 43 : 3S 46S.
4. Allain JP. Transfusion risks of yesterday and of today. Transfus Clin Biol 2003 10 : 1 5.
5. de Korte D, Marcelis JH, Verhoeven AJ, et al. Diversion of first blood volume results in a reduction of bacterial contamination for whole-blood collections. Vox Sang 2002 83 : 13 6.
6. Wagner SJ. Transfusion-transmitted bacterial infection: risks, sources and interventions. Vox Sang 2004 86 : 157 63.
7. Blajchman MA, Goldman M, Baeza F. Improving the bacteriological safety of platelet transfusions. Transfus Med Rev 2004 18 : 11 24.
8. te Boekhorst PA, Beckers EA, Vos MC, et al. Clinical significance of bacteriologic screening in platelet concentrates. Transfusion 2005 45 : 514 9.
9. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003 101 : 2426 33.
10. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004 104 : 1534 41.
11. Pathogen reduction in blood products. Publication 2003/16. Health Council of The Hague, The Netherlands 28 Aug 2003.
12. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in health and medicine. New York : Oxford University Press 1996.
13. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. New York : Oxford University Press 2003.
14. Sachs JD. Macroeconomics and health: investing in health for economic development. Geneva : World Health Organization 2001.
15. Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996 334 : 1685 90.
16. Sanquin annual report. Sanquin Blood Supply Foundation Amsterdam, 2003.
17. Korelitz JJ, Busch MP, Kleinman SH, et al. A method for estimating hepatitis B virus incidence rates in volunteer blood donors. Transfusion 1997 37 : 634 40.
18. Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996: Retrovirus Epidemiology Donor Study (REDS) JAMA 2000 284 : 229 35.
19. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002 42 : 975 9.
20. de Korte D, Curvers J, de Kort WL, et al. Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands. Transfusion 2006 46 : 476 85.
21. Morrow JF, Braine HG, Kickler TS, et al. Septic reactions to platelet transfusions: a persistent problem. JAMA 1991 266 : 555 8.
22. Yomtovian R, Lazarus HM, Goodnough LT, et al. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion 1993 33 : 902 9.
23. Kuehnert MJ, Roth VR, Haley NR, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001 41 : 1493 9.
24. Ness P, Braine H, King K, et al. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion 2001 41 : 857 61.
25. Perez P, Salmi LR, Follea G, et al. Determinants of transfusion- associated bacterial contamination: results of the French BACTHEM Case-Control Study. Transfusion 2001 41 : 862 72.
26. Stainsby D, et al. Serious hazards of transfusion: SHOT Annual Report, 2003. Manchester : SHOT Office 2004.
27. Brecher ME, Hay SN. Bacterial contamination of blood components. Clin Microbiol Rev 2005 18 : 195 204.
28. Evans M, Hastings NAJ, Peacock JB. Statistical distributions. 3rd ed. New York : Wiley 2000.
29. Jackson BR, Busch MP, Stramer SL, et al. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003 43 : 721 9.
30. AuBuchon JP. Cost-effectiveness of new blood safety technologies. Dev Biol Stand 2000 102 : 211 5.
31. Lopez-Plaza I, Weissfeld J, Triulzi DJ. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets. Transfusion 1999 39 : 925 32.
32. Pereira A. Cost-effectiveness analysis and the selection of blood products. Curr Opin Hematol 2000 7 : 420 5.
33. Bell CE, Botteman MF, Gao X, et al. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther 2003 25 : 2464 86.
34. Pereira A. Health and economic impact of posttransfusion hepatitis B and cost-effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union. Transfusion 2003 43 : 192 201.
35. Pereira A, Sanz C. A model of the health and economic impact of posttransfusion hepatitis C. application to cost-effectiveness analysis of further expansion of HCV screening protocols. Transfusion 2000 40 : 1182 91.
36. Brecher ME, Hay SN, Rothenberg SJ. Validation of BacT/ALERT plastic culture bottles for use in testing of whole-blood-derived leukoreduced platelet-rich-plasma-derived platelets. Transfusion 2004 44 : 1174 8.
37. Brecher ME, Hay SN, Rose AD, et al. Evaluation of BacT/ALERT plastic culture bottles for use in testing pooled whole blood-derived leukoreduced platelet-rich plasma platelets with a single contaminated unit. Transfusion 2005 45 : 1512 7.
38. Knutson F, Alfonso R, Dupuis K, et al. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang 2000 78 : 209 16.
39. Hofland M, Verhoeven AJ. [Cost reduction through improved stock management of trombocyte products]. NVB-Bulletin 2004 Jan 3.
40. Picker SM, Speer R, Gathof BS. Evaluation of processing characteristics of photochemically treated pooled platelets. target requirements for the INTERCEPT Blood System comply with routine use after process optimization. Transfus Med 2004 14 : 217 23.
41. Polder JJ, Takken J, Meerding WJ, Kommer GJ, Stokx LJ. Costs of illness in The Netherlands (Kosten van ziekte in Nederland). RIVM-report number 270751005. Bilthoven : Rijksinstituut voor Volksgezondheid en Milieu 2002.
42. van der Poel CL, van Noord PA, Smit S, et al. [Epidemiology of blood transfusions.] Ned Tijdschr Geneeskd 1999 143 : 1639.
43. Wallis JP, Wells AW, Matthews JN, et al. Long-term survival after blood transfusion: a population based study in the North of England. Transfusion 2004 44 : 1025 32.
44. Health statistics: deaths by causes [monograph on the Internet]. The Hague : Statistics Netherlands (CBS) 2001. Available from: http://www.cbs.nl/nl- NL/default.htm
45. Prevolnik Rupel V. 20th Plenary meeting of the EuroQol group. Republic of Slovenia : Ministry of Health 2005.
46. Brecher ME, Hay SN. Improving platelet safety: bacterial contamination of platelets. Curr Hematol Rep 2004 3 : 121 7.
47. McDonald CP, Roy A, Mahajan P, et al. Relative values of the interventions of diversion and improved donor-arm disinfection to reduce the bacterial risk from blood transfusion. Vox Sang 2004 86 : 178 82.
48. Blajchman MA, Goldman M, Freedman JJ, et al. Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction. Transfus Med Rev 2001 15 : 1 20.
49. Munksgaard L, Albjerg L, Lillevang ST, et al. Detection of bacterial contamination of platelet components: six years' experience with the BacT/ALERT system. Transfusion 2004 44 : 1166 73.
50. Handling risks (Omgaan met risico's). Zoetermeer : Ministry of VROM 1989 :